| http://www.w3.org/ns/prov#value | - As with PV, increasing numbers of cases of patients with ET and PMF are now being described with new additional mutations in the complementary thrombopoietin pathway (MPL genetic mutations of exon 10.) Identification of an appropriate mutation obviates the need for clinical, morphological or other evaluation to demonstrate a reactive cause of disease.
|
